Cibus (CBUS) AI Stock Analysis

• Market Cap: $73.83M
• Dividend Yield: N/A
• Average Volume (3M): 191.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.20
• Revenue Growth: -8.64%
• EPS Growth: 85.68%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 52,707,626
• 10 Day Avg. Volume: 123,890
• 30 Day Avg. Volume: 191,421
• PEG Ratio: <0.01
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 15.15
• P/FCF Ratio: -1.10
• Enterprise Value/Market Cap: 4.14
• Enterprise Value/Revenue: 80.52
• Enterprise Value/Gross Profit: 127.28
• Enterprise Value/Ebitda: -3.57
• 1Y Price Target: $20.00
• Price Target Upside: 1487.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -2.39
• Revenue Forecast (FY): $4.34M

• Rating: 43 Neutral
• Price Target: $1.50 ▲(19.05% Upside)

Cibus's overall stock score is primarily impacted by its weak financial performance and valuation. Despite some positive developments in commercialization and cost reduction, the company's ongoing financial instability and bearish technical indicators weigh heavily on the score.

Positive Factors

Strategic Partnerships

These agreements expand Cibus's market reach and potential revenue streams, leveraging their gene-editing technology to secure significant annual royalties.

Regulatory Advancements

Regulatory progress enhances Cibus's global market access, allowing for broader commercialization of gene-edited products, which supports long-term growth.

Cost Reduction

Operational streamlining and cost reduction efforts improve financial efficiency, potentially increasing profitability and extending cash runway.

Negative Factors

Revenue Decline

The decline in revenue reflects challenges in partner-funded program activities, impacting short-term financial performance and potentially hindering growth.

Cash Runway Concerns

Limited cash reserves pose a risk to Cibus's ability to fund operations beyond early Q2 2026, potentially affecting strategic initiatives and financial stability.

Regulatory Delays

Delays in EU regulatory approvals could postpone market entry and revenue generation, impacting Cibus's growth strategy and competitive positioning.

Cibus Business Overview & Revenue Model

Company Description

Cibus (CBUS) is a biotechnology company focused on developing innovative solutions for crop enhancement and agricultural productivity. The company operates primarily in the agricultural biotechnology sector, specializing in the creation of gene-edited crops that are designed to improve yield, disease resistance, and environmental sustainability. Cibus aims to provide farmers with advanced tools to optimize their farming practices and increase food production while addressing global challenges such as climate change and food security.

How the Company Makes Money

Cibus generates revenue primarily through the licensing of its proprietary gene-editing technology and the sale of its gene-edited crop products. The company partners with agricultural firms and seed companies to develop and commercialize its products, allowing it to earn royalties on sales made by its partners. Additionally, Cibus may engage in strategic collaborations or joint ventures that provide upfront payments or milestone payments based on the achievement of specific development goals. The company’s focus on innovative agricultural solutions positions it to benefit from increasing demand for sustainable agricultural practices, further contributing to its revenue streams.

Cibus Financial Statement Overview

Summary

Cibus faces significant financial challenges, with persistent losses and declining revenues. The balance sheet shows limited equity and negative returns, and cash flow issues further exacerbate the company's financial instability.

Income Statement

Cibus has experienced significant revenue volatility, with a notable decline in TTM revenue growth. The company shows negative net profit and EBIT margins, indicating ongoing profitability challenges. Despite a high gross profit margin, the overall financial performance is weak due to substantial losses.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. However, the negative return on equity indicates that the company is not generating returns for shareholders. The equity ratio is relatively low, reflecting a limited buffer against liabilities.

Cash Flow

Cibus's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth is negative, and the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. The company struggles to generate positive cash flow, posing a risk to financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.79M	4.26M	1.82M	157.00K	25.99M	23.85M
Gross Profit	2.40M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
EBITDA	-85.62M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
Net Income	-118.90M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet
Total Assets	330.23M	350.07M	544.41M	22.42M	37.19M	63.33M
Cash, Cash Equivalents and Short-Term Investments	23.89M	14.43M	32.70M	3.43M	13.82M	29.00M
Total Debt	33.95M	36.29M	24.62M	13.91M	17.88M	19.76M
Total Liabilities	278.20M	252.24M	206.12M	15.19M	23.06M	26.45M
Stockholders Equity	50.40M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow
Free Cash Flow	-51.71M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
Operating Cash Flow	-51.17M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
Investing Cash Flow	-548.00K	-808.00K	55.06M	-1.52M	11.20M	-13.48M
Financing Cash Flow	46.80M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Positive. The current price of 1.26 is below the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.41, and below the 200-day MA of 1.73, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 58.06 is Neutral, neither overbought nor oversold. The STOCH value of 81.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	53 Neutral	$76.47M	-0.69	-49.78%	―	-82.16%	14.58%
CRVO	52 Neutral	$64.95M	-2.69	-71.42%	―	-38.81%	-76.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XFOR	44 Neutral	$318.27M	―	-156.87%	―	2925.73%	-294.29%
CBUS	43 Neutral	$73.83M	―	-149.99%	―	-8.64%	85.68%
ABVC	43 Neutral	$68.53M	-12.64	-40.32%	―	56.52%	75.22%
OKYO	38 Underperform	$73.72M	―	―	―	―	―

Cibus Corporate Events

Cibus, Inc. Earnings Call Highlights Progress and Challenges

Cibus, Inc. Earnings Call Reflects Cautious Optimism Amid Challenges

Cibus, Inc. Reports Q3 2025 Financial Results

Cibus, Inc., a leading agricultural technology company, specializes in developing and licensing plant traits to seed companies, focusing on enhancing productivity and sustainability in the agricultural sector through advanced gene editing technologies.

Cibus Appoints Craig Wichner to Board of Directors

On November 5, 2025, Cibus, Inc. appointed Craig Wichner to its Board of Directors and its Strategy Committee. Wichner, founder of Farmland LP, brings extensive experience in organic and regenerative farmland management. His appointment is expected to enhance Cibus’s strategic operations, given his background in sustainable growth and investment management. The company has entered into a standard indemnification agreement with Wichner and will compensate him with a cash retainer and equity compensation for his board service.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Appoints Carlo Broos as Chief Financial Officer

Cibus, Inc. has appointed Cornelis (Carlo) Broos as its Chief Financial Officer, effective retroactively from September 18, 2025. Mr. Broos, who has been with the company since 2011, previously served as the Interim CFO and has extensive experience in finance and accounting. This appointment is accompanied by an Executive Employment Agreement that outlines his compensation and severance benefits, reflecting the company’s commitment to strengthening its financial leadership.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Appoints Kimberly A. Box to Board

On September 11, 2025, Cibus, Inc. appointed Kimberly A. Box to its board of directors. Ms. Box will serve on several committees, including the Compensation Committee, Nominating and Corporate Governance Committee, and a special committee evaluating strategic alternatives to maximize shareholder value. Her extensive experience includes roles at Gatekeeper Innovation, Hewlett Packard, and various other boards, bringing valuable expertise to Cibus. The appointment reflects Cibus’s commitment to enhancing its governance and strategic direction, potentially impacting shareholder value positively.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus, Inc. Earnings Call: Progress Amidst Challenges

Cibus, Inc. Earnings Call: Progress Amidst Challenges